PRLD Stock Summary and Trading Ideas (Prelude Therapeutics | NASDAQ:PRLD)

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Prelude Therapeutics trades on the NASDAQ stock market under the symbol PRLD.

As of February 19, 2026, PRLD stock price climbed to $2.27 with 196,893 million shares trading.

PRLD has a beta of 1.42, meaning it tends to be more sensitive to market movements. PRLD has a correlation of 0.05 to the broad based SPY ETF.

PRLD has a market cap of $142.70 million. This is considered a Micro Cap stock.

In the last 3 years, PRLD traded as high as $8.57 and as low as $.61.

The top ETF exchange traded funds that PRLD belongs to (by Net Assets): VTI, VXF, AVSC, DCOR.

PRLD has outperformed the market in the last year with a return of +139.2%, while the SPY ETF gained +13.1%. In the last 3 month period, PRLD beat the market returning +35.1%, while SPY returned +4.0%. However, in the most recent 2 weeks PRLD has underperformed the stock market by returning -1.3%, while SPY returned -0.2%.

PRLD support price is $1.99 and resistance is $2.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRLD shares will trade within this expected range on the day.